Sellas Life Sciences (SLS) Rises Ahead of Upcoming Clinical Trial Results

Sellas Life Sciences Group Inc. (NASDAQ:SLS) rose 12% as investors anticipated the release of phase 3 clinical trial data for its Galinpepimut-S treatment in acute myeloid leukemia patients, with speculation also pointing to potential takeover activity.

By Angelica Ballesteros Fri, July 17, 2026 at 11:11 PM GMT+3 3 min read · Yahoo Finance · July 17, 2026, 20:11 UTC

Sellas Life Sciences (SLS) Rises Ahead of Upcoming Clinical Trial Results

Topics: biotech clinical trials pharma takeover speculation

Read the full article at Yahoo Finance

More World news

Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC
Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures Seeking Alpha · November 12, 2026, 19:00 UTC
DPC Holdings PLC Reports Record Q3 Revenue Growth and Issues 2027 Financial Guidance Seeking Alpha · November 12, 2026, 19:01 UTC
Senate Minority Leader Schumer Demands Congressional Testimony from Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 18:59 UTC
Nvidia Shares Plunge Following CEO Jensen Huang's Departure Amid Investigation Motley Fool · November 12, 2026, 19:00 UTC
San Francisco Fed President Mary Daly Views AI as Transformative Investment Opportunity Seeking Alpha · November 12, 2026, 19:00 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC